Epigenomics AG

As of June 30, 2023, Epigenomics AG has 853,285.00 shares outstanding.

These figures are as of June 30, 2023. The price-to-sales ratio is 8.23, and the price-to-book ratio stands at -0.04.

These figures are as of June 30, 2023. The EV/Sales ratio of 1.02 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative.

As of June 30, 2023, Epigenomics AG maintains a current ratio of 1.93, meaning it holds 1.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 18.65, indicating elevated leverage, while an interest coverage ratio of -180.60 demonstrates limited ability to service its debt obligations.

These figures cover the twelve months ended June 30, 2023. Return on assets (ROA) is negative at -131.18, reflecting losses generated across the asset base. Inventory turnover of 2.73 indicates how many times Epigenomics AG sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2023, Epigenomics AG posted a gross margin of 76.56, reflecting its pricing power and cost economics. The operating margin of -4,071.65 and net profit margin of -3,636.16 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2023. Free cash flow yield is negative at -312.21: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield reaches 9.85, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Epigenomics AG shareholders.

Epigenomics AG's most recent stock split took place on December 8, 2023 with a 5:1 split ratio.

As of June 30, 2023, Epigenomics AG has an Altman Z-Score of -48.00, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.